Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atreca Inc Cl A (BCEL)

Atreca Inc Cl A (BCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Atreca Inc Cl A 835 INDUSTRIAL ROAD SUITE 400 SAN CARLOS CA 94070 USA

www.atreca.com P: 650-595-2595

Description:

Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca's approach relies on the human immune system to direct it to unique antibody-target pairs from patients experiencing a clinically meaningful, active immune response against their tumors. These unique antibody-target pairs represent a potentially novel and previously unexplored landscape of immuno-oncology targets.

Key Statistics

Overview:

Market Capitalization, $K 3,812
Enterprise Value, $K -27,008
Shares Outstanding, K 39,624
Annual Sales, $ 0 K
Annual Net Income, $ -97,160 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -36,220 K
EBIT, $ -99,230 K
EBITDA, $ -92,090 K
60-Month Beta 1.02
% of Insider Shareholders 11.30%
% of Institutional Shareholders 37.47%
Float, K 35,146
% Float 88.70%
Short Volume Ratio 0.34

Growth:

1-Year Return -89.60%
3-Year Return -99.02%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.39 on 11/14/23
Latest Earnings Date 05/08/24 [--]
Earnings Per Share ttm -1.97
EPS Growth vs. Prev Qtr 20.41%
EPS Growth vs. Prev Year 35.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

BCEL Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % 0.00%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 0.33
Book Value/Share 0.27
Interest Coverage -2.09
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar